publication date: Apr 30, 2018
|
author/source: BioIVT
BioIVT has acquired Ascendance Biotechnology and will be adding the HepatoPac®, HepatoMune™ and HepatoStem™ liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.
The joining of the two companies is an exciting opportunity to combine BioIVT’s considerable expertise in hepatocytes and tissues with Ascendance/Hepregen’s highly functional, in vitro liver models.
As a valued client you can expect:
- Access to high-quality TRANSPORTER CERTIFIED™ hepatocytes to ensure consistent in vivo relevant data for your research.
- Help in assessing the pharmacokinetics of compounds in the liver through the efficient design and implementation of research programs.
- Expanded portfolio to include HepatoPac® products which closely mimic the function of a human liver and allow greater understanding of the toxicity resulting from long-term exposure to chemical compounds.
We encourage you to learn more about the new products offered by the combined company.
Together with Ascendance/Hepregen, we will continue to strive to meet the ever-changing needs of our clients. We are dedicated to maintaining and enhancing the quality of our products, support, and service that you have come to expect.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.